© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dasatinib belongs to the class of tyrosine kinase inhibitors, playing a key role in the management of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Doctors rely on Dasatinib for its targeted approach, interfering with the pathways cancers use to grow. Researchers and manufacturers often receive Dasatinib as a raw material for further formulation, testing, or integration into tablet creation.
The molecular formula for Dasatinib is C22H26ClN7O2S with a molecular weight of approximately 488.01 g/mol. Its chemical structure presents a fusion of thiazole and pyrimidine rings, giving it both stability and the ability to interact with multiple cellular targets. Physically, this molecule stands distinguished by its nitrogen-rich scaffold, which supports hydrogen bond formation, crucial for drug-receptor interactions. The purity of Dasatinib as a material directly affects clinical effectiveness, so analytical methods such as NMR, LC-MS, and IR spectroscopy are used to confirm identity and composition.
Dasatinib usually appears as a white to slightly yellow crystalline powder. Some manufacturers may supply it as fine flakes or in pearl form for easier handling, depending on production needs. It exhibits low solubility in water but high solubility in organic solvents like DMSO and ethanol, which assists in solution-based quality testing or formulation. Density calculations place it around 1.43 g/cm³, and it remains stable under normal storage temperatures, though keeping it away from light and moisture preserves its integrity. Handling Dasatinib powder should always occur in a controlled lab environment, using protective equipment to limit inhalation or direct skin exposure.
Product specifications list Dasatinib in forms such as powder, crystalline solid, or, less commonly, as a prepared solution in research-grade solvents. The substance offers flexibility to compounders but demands precision to avoid loss of activity through degradation or contamination. Batch testing routinely covers assessment for ash, loss on drying, melting range (around 280–285°C), and specific optical rotation. In research labs, technicians may prepare Dasatinib solutions by dissolving the powder into measured volumes; this calls for calibrated glassware and accurate measurement, given the material’s potency.
Shipping and customs require the proper Harmonized System Code for Dasatinib, which typically falls under 2942.00. Don’t ignore the paperwork since mislabeling can halt supply chains or affect compliance with global trade laws. Storage rooms keep Dasatinib away from incompatible chemicals such as strong bases or oxidants. Exposure to raw Dasatinib can pose hazards—evidence from safety data and workplace observations point to irritation of skin and eyes, and inhalation can be harmful. GHS classification assigns it labels such as ‘harmful’ or ‘hazardous’ due to its bioactivity profile. Only trained staff should handle the bulk material, and spill management protocols matter more here than in the case of low-potency research chemicals.
Pharmaceutical manufacturers use Dasatinib in the production of finished drug products, quality control testing, and ongoing research to test analogs or new delivery forms. Every step, from raw powder weighing to blending, asks for caution and accuracy since minor variations shift therapeutic outcomes. The high price and regulatory scrutiny drive efforts to minimize waste and improve yields. In my own experience, each milligram of Dasatinib demands close attention—a lesson shared by both seasoned lab technicians and industry newcomers. The global push for anti-cancer compounds keeps making Dasatinib a vital chemical, with efforts underway to develop safer, greener synthesis methods and improved risk management plans in the workplace.
Factories and academic labs face challenges managing dust control, tracking batch numbers, and ensuring every barcoded container follows legal requirements from source to disposal. Stakeholders balance commercial benefits and clinical demand, keeping occupational safety, patient health, and regulatory approval in sharp focus. Dasatinib’s presence on hazardous substance lists prompts companies to invest in ventilation, secure packaging, and spill response training. Integrating real-world safety lessons, such as clear labeling and standardized PPE usage, reduces risks for workers with hands-on access. The need for effective anti-leukemia drugs keeps Dasatinib solidly positioned in pharmaceutical development, but the industry must stay ahead of the curve on sustainability and ethical sourcing for every kilogram produced.
